AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01923207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, subcutaneous administration
Trial: NCT03869905
Drug: Aquamin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
Trial: NCT01311167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of 2 mg of placebo for 4 days
Trial: NCT00796926
Drug: Systane Ultra eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times a day
Trial: NCT00796926
Drug: Refresh eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times a day
Trial: NCT02878161
Drug: methotrexate(necessary)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
Trial: NCT02878161
Drug: Glucocorticoids (permitted,not necessary)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
Trial: NCT02323100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 am, 4pm and midnight
Trial: NCT03992456
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01789398
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
Trial: NCT01420094
Drug: Acetaminophen (Tylenol extra strength)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Trial: NCT01420094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Trial: NCT01901393
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01901393
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00039572
Drug: boronophenylalanine-fructose complex
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02181673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
Trial: NCT03976648
Drug: GLPG1690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablets of GLPG1690 to be administered orally
Trial: NCT00296205
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01589991
Drug: Toothpaste
RxNorm normalized name: TOOTHPASTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
Trial: NCT00833664
Drug: Lamisil® 250 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg
Trial: NCT04469998
Drug: AXR-270 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXR-270 Topical Eyelid Cream Vehicle
Trial: NCT00312650
Drug: liposomal doxorubicin and gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02657473
Drug: Saline 0.9% inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00476008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet placebo morning and evening (BID) for 12 months
Trial: NCT06131476
Drug: Blink® Tears eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Drops
Trial: NCT06131476
Drug: Investigational lipid eye drops
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drops
Trial: NCT01615822
Drug: OZ439 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 100mg oral suspension, single dose
Trial: NCT01292824
Drug: ITX 5061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
Trial: NCT01615822
Drug: OZ439 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 400mg oral suspension, single dose
Trial: NCT01615822
Drug: MQ 250 mg, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 250 mg tablet, single dose
Trial: NCT01615822
Drug: MQ 750mg, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 750mg oral tablet, single dose
Trial: NCT01615822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00539006
Drug: FPNS
RxNorm normalized name: Fluticasone Propionate and Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fluticasone propionate nasal spray
Trial: NCT00539006
Drug: placebo FPNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo nasal spray matching fluticasone propionate nasal spray
Trial: NCT01764776
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225
Trial: NCT03921645
Drug: aerosol antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
Trial: NCT01357850
Drug: GSK716155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK716155
Trial: NCT01357850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04546984
Drug: HEC96719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2：Mulltiple doses up to 10 days
Trial: NCT04274998
Drug: [18F]NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
Trial: NCT04274998
Drug: [11C]PBR28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
Trial: NCT01310205
Drug: SCV-07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
Trial: NCT02891070
Drug: FS VH S/D 500 s-apr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01874340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at predefined visits over the 6-month treatment phase.
Trial: NCT01874340
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 will be administered at predefined visits over the 6-month treatment phase.
Trial: NCT01132781
Drug: Theophylline (Intervention Group)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily of slow release theophylline
Trial: NCT01132781
Drug: Placebo (Placebo Group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily of placebo drug
Trial: NCT03926611
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, orally, twice daily from Day 1 to 85
Trial: NCT00389987
Drug: MK0826, /Duration of Treatment : 8 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003452
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01146327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of placebo will be given once daily for 2 weeks.
Trial: NCT00484757
Drug: Orexine A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06354127
Drug: Botox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test drug or control drug is injected on the day of administration.
Trial: NCT01652482
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Trial: NCT01652482
Drug: MEHD7945A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
Trial: NCT00481091
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT00475306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01042041
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via transarterial/hepatic chemoembolization
Trial: NCT03176537
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgel (50mg testosterone), gel, daily
Trial: NCT03176537
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, gel, daily
Trial: NCT02195271
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01490905
Drug: Theraprofen
RxNorm normalized name: Theraprofen-90 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
Trial: NCT01490905
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg once daily for 28 days.
Trial: NCT02536417
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
Trial: NCT00824993
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
Trial: NCT03890042
Drug: Gestodene-Ethinyl Estradiol
RxNorm normalized name: gestodene-ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynera tablet once daily
Trial: NCT01651806
Drug: Males Weighted Dose TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted dose--20mg/kg of the drug will be given
Trial: NCT00650806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally once daily for 12 weeks.
Trial: NCT04765228
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
Trial: NCT02834793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo in Randomization phase.
Trial: NCT01523977
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 IV on days 4 and 5
Trial: NCT04045405
Drug: CDR132L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration
Trial: NCT03835949
Drug: TJ004309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody to CD73
Trial: NCT01043913
Drug: Guarana extract
RxNorm normalized name: guarana extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guarana extract 50mg q12 hours for 21 days
Trial: NCT02549924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, 500 mg 3 times daily with the first bite of each meal
Trial: NCT01876004
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2, IM (intramuscularly), single dose
Trial: NCT01876004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed Placebo IM (intramuscularly), single dose
Trial: NCT00838084
Drug: LY2811376
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT00838084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT01034748
Drug: [14C]PF00299804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 45 mg oral dose of radiolabelled PF-00299804
Trial: NCT01159652
Drug: bedtime placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01159652
Drug: middle of the night placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00381134
Drug: spironolactone 25 mg orally once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00381134
Drug: placebo once orally once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02925650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solid dosage form capsule
Trial: NCT00314262
Drug: Erlotinib & Celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months.
Trial: NCT04498260
Drug: Oral steroid - predonisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (predonisolone)
Trial: NCT00016406
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00823680
Drug: RO5027838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg po qd for 4 weeks
Trial: NCT00823680
Drug: RO5093151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg po bid for 4 weeks
Trial: NCT03755960
Drug: routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
Trial: NCT01363349
Drug: CYP-1020
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
Trial: NCT01958489
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02198820
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with proposal, rocuronium and sufentanil
Trial: NCT00741026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
Trial: NCT01902992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01702493
Drug: Cap SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
Trial: NCT01702493
Drug: Tab SRT2104 slow release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New 250 mg SRT2104 mesylate salt slow release tablet
Trial: NCT01702493
Drug: Tab SRT2104 intermediate release
RxNorm normalized name: PREVOTELLA INTERMEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New 250 mg SRT2104 mesylate salt intermediate release tablet
Trial: NCT01702493
Drug: Selected formulations of SRT2104 from Part 1
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
Trial: NCT01702493
Drug: Selected formulations of SRT2104 from Part 1 single alternative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
Trial: NCT03099265
Drug: neoadjuvant mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
Trial: NCT01717599
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
Trial: NCT01717599
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
Trial: NCT01433289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01002417
Drug: MCS-2 15 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
Trial: NCT01002417
Drug: MCS-2 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
Trial: NCT01002417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two matching placebo soft-gel capsules, oral daily for 12 weeks.
Trial: NCT00324259
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01534897
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
Trial: NCT01462253
Drug: Clofarabine, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
Trial: NCT03613961
Drug: Anesthetics
RxNorm normalized name: ANESTHETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
Trial: NCT01383343
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01383343
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00226759
Drug: OMS103HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
Trial: NCT00226759
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Trial: NCT00079027
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00117494
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00117494
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00220129
Drug: Epirubicin, Cisplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00452361
Drug: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation